Prevention Epicenters Program: Protecting Patients from Infections, Antibiotic Resistance andOther Adverse Events

点击翻译按钮获取中文摘要

We have been a member of the Prevention Epicenters (Cycle II, RFA-CK-18-001) since 2015. Our core investigative group has over 430 publications in the area of healthcare-associated infections and antibiotic resistance which have been cited over 12,000 times. The leaders of our core projects have had more than 27 grants and contracts as principal investigators and have over 350 publications in the scientific expertise areas in the RFA. We have collaborated with the current Epicenter II sites on 53 publications since 2015 and have collaborated with current Epicenter I sites on 35 publications. One of our group’s greatest strengths is our ability to leverage our experience and expertise to complete collaborative projects among the existing Epicenters and other healthcare institutions. We propose core and collaborative projects that are innovative, feasible and responsive to CDC priority areas. Our core proposals are: 1. State-wide prevalence of multi-drug resistant Acinetobacter baumannii in ventilated patients in acute and long-term facilities. 2. Evaluation of use and usability of surveillance for hospital-onset bacteremia and fungemia in acute care facilities 3. Decreasing Transmission of Multi-drug Resistant Organisms in Chronic Ventilator Units in Nursing Homes 4. Assessing feasibility of a targeted approach to contact precautions for MRSA in the acute care setting 5. Improving clinician microbiology test interpretation and use in all healthcare settings Our collaborative project proposals are: 1. Risk factors associated with transmission of Candida auris in the acute care setting (Large Project) 2. Diagnostic Stewardship for Ventilator Associated Pneumonia: A cluster-randomized crossover trial of a hybrid order-review and laboratory reporting intervention in acute care facilities (Medium project) Through these projects and the development of other collaborative projects, we look forward to contributing to the Prevention Epicenters Program: Protecting Patients from Infections, Antibiotic Resistance and Other Adverse Events.